KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Raw Materials (2016 - 2025)

Historic Raw Materials for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $57.0 million.

  • Supernus Pharmaceuticals' Raw Materials rose 39250.71% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.0 million, marking a year-over-year increase of 39250.71%. This contributed to the annual value of $11.1 million for FY2024, which is 3162.71% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Raw Materials stood at $57.0 million, which was up 39250.71% from $8.4 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Raw Materials' 5-year high stood at $57.0 million during Q3 2025, with a 5-year trough of $7.3 million in Q4 2021.
  • Its 5-year average for Raw Materials is $18.1 million, with a median of $15.9 million in 2024.
  • In the last 5 years, Supernus Pharmaceuticals' Raw Materials plummeted by 7349.69% in 2022 and then soared by 39250.71% in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Raw Materials stood at $7.3 million in 2021, then soared by 238.84% to $24.8 million in 2022, then crashed by 34.43% to $16.3 million in 2023, then tumbled by 31.63% to $11.1 million in 2024, then skyrocketed by 412.16% to $57.0 million in 2025.
  • Its Raw Materials stands at $57.0 million for Q3 2025, versus $8.4 million for Q2 2025 and $8.7 million for Q1 2025.